Optimal Gestational Weight Gain for Women With Obesity.


Journal

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
ISSN: 1701-2163
Titre abrégé: J Obstet Gynaecol Can
Pays: Netherlands
ID NLM: 101126664

Informations de publication

Date de publication:
11 2022
Historique:
received: 28 05 2022
revised: 13 07 2022
accepted: 14 07 2022
pubmed: 12 8 2022
medline: 24 11 2022
entrez: 11 8 2022
Statut: ppublish

Résumé

To determine the optimal gestational weight gain interval for women with obesity in order to minimize neonatal and maternal adverse events. Secondary analysis of the QUARISMA trial, including women with obesity who delivered a full-term singleton in cephalic presentation from 2008 to 2011 in Québec. The primary outcome was a composite risk of major neonatal morbidity. Secondary outcomes were composite risks of major maternal morbidity, minor neonatal and maternal morbidity, and cesarean delivery. Various ranges of weight gain were compared with the current recommendations (reference group) using logistic regression to identify an optimal gestational weight gain interval. In a secondary analysis, women with obesity were stratified by obesity class (I-III). Among 16 808 eligible women with obesity, 3270 gained less weight than recommended, 4355 gained weight as recommended (5-9.09 kg), and 9183 gained more weight than recommended. Optimal gestational weight change for all women with obesity was -1 to +4 kg and was associated with reduced risk of major neonatal morbidity (aOR 0.49; 95%CI 0.33-0.73, P < 0.001) compared with the reference group. Analysis by class of obesity showed a reduced risk of major neonatal morbidity with a weight change of -1 to +4 kg for class I, -2 to +2 for class II), and -2 to +3 kg for class III. Compared with the current guidelines, a gestational weight change of -1 to +4 kg is associated with reduced risk of adverse perinatal outcomes. While similar findings were seen among women with class I obesity, women with class II or III obesity could benefit from a lower weight gain.

Identifiants

pubmed: 35952925
pii: S1701-2163(22)00470-4
doi: 10.1016/j.jogc.2022.07.006
pii:
doi:

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1143-1152

Informations de copyright

Copyright © 2022 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.

Auteurs

Laurence Bujold (L)

Research Center of CHU de Québec, Laval University, Québec City, QC.

François Audibert (F)

Department of Obstetrics and Gynecology, Faculty of Medicine, University of Montréal, Montréal, QC.

Nils Chaillet (N)

Research Center of CHU de Québec, Laval University, Québec City, QC; Department of Obstetrics and Gynecology, Faculty of Medicine, Laval University, Québec City, QC. Electronic address: nils.chaillet@fmed.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH